194 related articles for article (PubMed ID: 30251395)
1. Cytotoxic activity of difluoromethylornithine compared with fenretinide in neuroblastoma cell lines.
Makena MR; Cho HE; Nguyen TH; Koneru B; Verlekar DU; Hindle A; Kang MH; Reynolds CP
Pediatr Blood Cancer; 2018 Dec; 65(12):e27447. PubMed ID: 30251395
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxicity and molecular activity of fenretinide and metabolites in T-cell lymphoid malignancy, neuroblastoma, and ovarian cancer cell lines in physiological hypoxia.
Song MM; Makena MR; Hindle A; Koneru B; Nguyen TH; Verlekar DU; Cho H; Maurer BJ; Kang MH; Reynolds CP
Anticancer Drugs; 2019 Feb; 30(2):117-127. PubMed ID: 30272587
[TBL] [Abstract][Full Text] [Related]
3. Reactive Oxygen Species Mediates the Synergistic Activity of Fenretinide Combined with the Microtubule Inhibitor ABT-751 against Multidrug-Resistant Recurrent Neuroblastoma Xenografts.
Chen NE; Maldonado NV; Khankaldyyan V; Shimada H; Song MM; Maurer BJ; Reynolds CP
Mol Cancer Ther; 2016 Nov; 15(11):2653-2664. PubMed ID: 27530131
[TBL] [Abstract][Full Text] [Related]
4. The impact of retinoic acid treatment on the sensitivity of neuroblastoma cells to fenretinide.
Armstrong JL; Martin S; Illingworth NA; Jamieson D; Neilson A; Lovat PE; Redfern CP; Veal GJ
Oncol Rep; 2012 Jan; 27(1):293-8. PubMed ID: 21964808
[TBL] [Abstract][Full Text] [Related]
5. The chemopreventive agents 4-HPR and DFMO inhibit growth and induce apoptosis in uterine leiomyomas.
Broaddus RR; Xie S; Hsu CJ; Wang J; Zhang S; Zou C
Am J Obstet Gynecol; 2004 Mar; 190(3):686-92. PubMed ID: 15042000
[TBL] [Abstract][Full Text] [Related]
6. DFMO inhibition of neuroblastoma tumorigenesis.
Gandra D; Mulama DH; Foureau DM; McKinney KQ; Kim E; Smith K; Haw J; Nagulapally A; Saulnier Sholler GL
Cancer Med; 2024 May; 13(9):e7207. PubMed ID: 38686627
[TBL] [Abstract][Full Text] [Related]
7. AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport.
Samal K; Zhao P; Kendzicky A; Yco LP; McClung H; Gerner E; Burns M; Bachmann AS; Sholler G
Int J Cancer; 2013 Sep; 133(6):1323-33. PubMed ID: 23457004
[TBL] [Abstract][Full Text] [Related]
8. Probenecid increases renal retention and antitumor activity of DFMO in neuroblastoma.
Schultz CR; Swanson MA; Dowling TC; Bachmann AS
Cancer Chemother Pharmacol; 2021 Oct; 88(4):607-617. PubMed ID: 34129075
[TBL] [Abstract][Full Text] [Related]
9. Fenretinide-induced caspase-8 activation and apoptosis in an established model of metastatic neuroblastoma.
Raguénez G; Mühlethaler-Mottet A; Meier R; Duros C; Bénard J; Gross N
BMC Cancer; 2009 Mar; 9():97. PubMed ID: 19331667
[TBL] [Abstract][Full Text] [Related]
10. Effect of polyamine depletion by alpha-difluoromethylornithine or (2R,5R)-6-heptyne-2,5-diamine on drug-induced topoisomerase II-mediated DNA cleavage and cytotoxicity in human and murine leukemia cells.
Bakic M; Chan D; Freireich EJ; Marton LJ; Zwelling LA
Cancer Res; 1987 Dec; 47(24 Pt 1):6437-43. PubMed ID: 2824033
[TBL] [Abstract][Full Text] [Related]
11. Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators.
Batra S; Reynolds CP; Maurer BJ
Cancer Res; 2004 Aug; 64(15):5415-24. PubMed ID: 15289350
[TBL] [Abstract][Full Text] [Related]
12. P450 inhibitor ketoconazole increased the intratumor drug levels and antitumor activity of fenretinide in human neuroblastoma xenograft models.
Lopez-Barcons L; Maurer BJ; Kang MH; Reynolds CP
Int J Cancer; 2017 Jul; 141(2):405-413. PubMed ID: 28340497
[TBL] [Abstract][Full Text] [Related]
13. Fenretinide via NOXA Induction, Enhanced Activity of the BCL-2 Inhibitor Venetoclax in High BCL-2-Expressing Neuroblastoma Preclinical Models.
Nguyen TH; Koneru B; Wei SJ; Chen WH; Makena MR; Urias E; Kang MH; Reynolds CP
Mol Cancer Ther; 2019 Dec; 18(12):2270-2282. PubMed ID: 31484706
[TBL] [Abstract][Full Text] [Related]
14. Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma.
Fang H; Harned TM; Kalous O; Maldonado V; DeClerck YA; Reynolds CP
Clin Cancer Res; 2011 Nov; 17(22):7093-104. PubMed ID: 21933888
[TBL] [Abstract][Full Text] [Related]
15. Pleiotropic effects of fenretinide in neuroblastoma cell lines and multicellular tumor spheroids.
Cuperus R; Tytgat GA; Leen R; Brites P; Bras J; Caron HN; Van Kuilenburg AB
Int J Oncol; 2008 May; 32(5):1011-9. PubMed ID: 18425327
[TBL] [Abstract][Full Text] [Related]
16. Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives.
Cooper JP; Reynolds CP; Cho H; Kang MH
Exp Biol Med (Maywood); 2017 Jun; 242(11):1178-1184. PubMed ID: 28429653
[TBL] [Abstract][Full Text] [Related]
17. Bak: a downstream mediator of fenretinide-induced apoptosis of SH-SY5Y neuroblastoma cells.
Lovat PE; Oliverio S; Corazzari M; Rodolfo C; Ranalli M; Goranov B; Melino G; Redfern CP; Piacentini M
Cancer Res; 2003 Nov; 63(21):7310-3. PubMed ID: 14612528
[TBL] [Abstract][Full Text] [Related]
18. Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity.
Shibina A; Seidel D; Somanchi SS; Lee DA; Stermann A; Maurer BJ; Lode HN; Reynolds CP; Huebener N
J Mol Med (Berl); 2013 Apr; 91(4):459-72. PubMed ID: 23052481
[TBL] [Abstract][Full Text] [Related]
19. Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)- retinamide in neuroblastoma cell lines.
Maurer BJ; Metelitsa LS; Seeger RC; Cabot MC; Reynolds CP
J Natl Cancer Inst; 1999 Jul; 91(13):1138-46. PubMed ID: 10393722
[TBL] [Abstract][Full Text] [Related]
20. A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma.
Saulnier Sholler GL; Gerner EW; Bergendahl G; MacArthur RB; VanderWerff A; Ashikaga T; Bond JP; Ferguson W; Roberts W; Wada RK; Eslin D; Kraveka JM; Kaplan J; Mitchell D; Parikh NS; Neville K; Sender L; Higgins T; Kawakita M; Hiramatsu K; Moriya SS; Bachmann AS
PLoS One; 2015; 10(5):e0127246. PubMed ID: 26018967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]